secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001171843-23-002790
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q1 ORLADEYO revenue $68.4M (+38% YoY); net loss narrows to $53.3M
--------------------------------------------------------------------------

- ORLADEYO net revenue $68.4M in Q1 2023 (+37.6% YoY); 46% more U.S. patients on therapy vs Q1 2022.
- Over 1,000 U.S. patients on ORLADEYO; new patient start forms up 20% YoY in Q1.
- Full-year 2023 ORLADEYO net revenue guidance set at no less than $320M.
- Entered new $450M loan agreement with Pharmakon; $300M drawn to repay Athyrium debt.
- R&D expense reduced 26% YoY to $48.4M; SG&A rose 39.6% to $47.9M on commercial investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/f8k_050323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer